THERAPY DOSSIER · th-f6e1a243e281

N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP), an endogenous tetrapeptide

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT01588756 ↗PHASE1/PHASE2completed

Development of a New Non-radioactive Test for Measuring Glomerular Filtration Rate Using the Tetrapeptide N-acetyl-Ser-Asp-Lys-Pro-amide (AcSDKP-NH2)

Healthy · Chronic Kidney Disease

Enrolment: 100 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30998852 ↗2019Reported benefit

-acetyl-seryl-aspartyl-lysyl-proline treatment protects heart against excessive myocardial injury and heart failure in mice.

MouseIschaemia-reperfusionCardiacC57BL/6Jmalen = 73 mice with myocardial infarction in protocol 1 (vehicle n…intraperitoneal continuous infusion by ALZET osmotic minipump1.6 mg/kg per dayminipump implanted 7 days before myocardial infarction in the acute rupture pro…

Model: Myocardial infarction by permanent ligation of the left anterior descending coronary artery

Cardiac rupture at 7 days fell from 60.5% in vehicle-treated to 23.3% in Ac-SDKP-treated mice, with reduced ICAM-1, macrophage infiltration, gelatinolytic activity, p53 and cardiomyocyte apoptosis, and increased capillary density in the infarct border, without change in infarct size. At 5 weeks Ac-…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.88. Machine-extracted fields require source verification.

Loading the evidence…